Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations

Cancer

Volumn 72, Issue 11 S, 1993, Pages 3502-3514

  Lum, Bert L ^a,b   Fisher, George A ^a   Brophy, Nathalie A ^a   Yahanda, Anne M ^a,c   Adler, Kent M ^a   Kaubisch, Sonja ^b   Halsey, Joanne ^a   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

cyclosporine; etoposide; modulation; multidrug resistance; pharmacokinetics; phase I trials

Indexed keywords

BEPRIDIL; CALMODULIN INHIBITOR; CEFOPERAZONE; CEFTRIAXONE; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; CYTARABINE; DAUNORUBICIN; DILTIAZEM; DIPYRIDAMOLE; DOXORUBICIN; ERYTHROMYCIN; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; MEGESTROL; MITOXANTRONE; MONOCLONAL ANTIBODY; NICARDIPINE; NIMODIPINE; PACLITAXEL; PROGESTERONE; QUINIDINE; TACROLIMUS; TAMOXIFEN; TERFENADINE; TOREMIFENE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

ADULT; AGED; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER PROTEINS; CLINICAL TRIALS; CYCLOSPORINE; DRUG RESISTANCE; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027518135     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19931201)72:11+<3502::AID-CNCR2820721618>3.0.CO;2-N     Document Type: Article

References (70)

1. Cancer statistics, 1990
2. Drug resistance in cancer
3. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response
4. Membrane‐mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells
5. Reduced permeability in CHO cells as a mechanism of resistance to colchicine
6. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells
7. Enhanced efflux of actinomycin D, vincristine and vinblastine in adriamycin‐resistant subline of P388 leukemia
8. Mammalian drug resistance gene: complete cDNA sequence indicates a strong homology to bacterial transport proteins
9. Internal duplication and homology with bacterial transport proteins in the mdr1 (P‐glycoprotein) gene from multidrug resistant human cells
10. The yeast STE6 gene codes a homologue of the mammalian multidrug resistance P‐glycoprotein
11. Reduced drug accumulation in multiply drug‐resistant human KB carcinoma cell lines
12. A Fickian diffusion transport process with features of transport catalysis: doxorubicin transport in human red blood cells
13. Inhibition by modulators of drug resistance of 3H‐vinblastine binding to plasma membranes of multidrug resistant and sensitive cells
14. Single cell analysis of daunomycin uptake and efflux in multidrug‐resistant and sensitive KB cells: effects of verapamil and other drugs
15. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P‐glycoprotein by a vinblastine analog
16. Expression of a multidrug‐resistant gene in human tumors and tissues
17. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug‐resistance gene
18. Expression of a multidrug resistance gene in human cancers
19. Distribution of multidrug resistance‐associated P‐glycoprotein in normal and neoplastic tissues
20. Detection of p‐glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance
21. High levels of human gene transcripts are related to previous chemotherapy in neuroblastoma
22. Clinical significance of multidrug resistance P‐glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
23. Molecular targets in oncology: implications of the multidrug resistance gene
24. P‐glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
25. Immunohistochemical detection of P‐glycoprotein: prognostic correlation in soft tissue sarcoma
26. Immunohistochemical analysis of P‐glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer
27. MDR1 gene expression and treatment outcome in acute myeloid leukemia
28. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity
29. Pharmacology of drugs that alter multidrug resistance in cancer
30. Circumvention of vincristine and adriamycin resistance in vitro and in‐vivo by calcium influx blockers
31. Potentiation of vincristine and adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors
32. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug‐resistant tumor cells
33. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with special emphasis on quinacrine
34. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma
35. In vivo circumvention of P‐glycoprotein‐mediated multidrug resistance of tumor cells with SDZ PSC 833
36. SDZ 280–446, a novel semisynthetic cyclopeptide: in vitro and in vivo circumvention of P‐glycoprotein mediated tumor cell multidrug resistance
37. Expression and activity of P‐glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
38. Expression of the multidrug resistance gene product (P‐glycoprotein) in human normal and tumor tissues
39. Identification of P‐glycoprotein in renal brush border membranes
40. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells
41. MDR genes in human cancer
42. Cellular localization of the multi‐drug resistance gene product P‐glycoprotein in normal tissues
43. Multidrug resistance gene family and chemical carcinogens
44. Bilirubin: a physiological substrate for the multidrug transporter
45. Progesterone interacts with P‐glycoprotein in multidrug resistant cells and in the endometrium of gravid uterus
46. Physiological function of P‐glycoprotein in brain capillary endothelial cells [abstract]
47. Brain microvascular endothelial cells express in vitro P‐glycoprotein activity: functional studies [abstract]
48. Energy‐dependent secretory transport of digoxin by renal tubular cells (LLC‐PK1)
49. Effects of verapamil on the pharmacokinetics of daunomycin in the rat
50. Induction of mdr expression by cholestasis: p‐glycoprotein functions as a biliary excretion pump [abstract]
51. The effect of verapamil on the pharmacokinetics of adriamycin
52. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts
53. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
54. Etoposide kinetics in patients with obstructive jaundice
55. Protein binding of etoposide in patients with cancer
56. Coinduction of MDR‐1 multidrug resistance and cytochrome P‐450 genes in rat liver by xenobiotics
57. High dose tamoxifen and five day continuous infusion vinblastine: a phase I trial of an inhibitor of the MDR1 phenotype
58. Multidrug‐resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer
59. Drug‐resistance in multiple myeloma and non‐Hodgkin's lymphoma: detection of P‐glycoprotein and potential circumvention by addition of verapamil to chemotherapy
60. Verapamil and adriamycin in the treatment of drug‐resistant ovarian cancer patients
61. Cyclosporin A modulation of doxorubicin: pharmacokinetics, response, and evaluation of the MTD
62. Biochemical modulation of anthracycline resistance in acute leukemia with cyclosporin‐A
63. A phase I‐II trial of cyclosporine with etoposide and mitoxantrone in advanced acute leukemia
64. Phase I trial of multidrug resistance modulation with cyclosporin‐A
65. In vivo modulation of doxorubicin by high dose progesterone. A phase I/pharmacokinetic study
66. Phase I/II trial of etoposide and cefoperazone in the treatment of refractory neoplasms
67. Feasibility of using quinine, a potential multidrug resistance‐reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia